Results 31 to 40 of about 8,267 (256)

Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine

open access: yesCellular and molecular neurobiology, 2021
Phenelzine (PLZ) is a monoamine oxidase (MAO)-inhibiting antidepressant with anxiolytic properties. This multifaceted drug has a number of pharmacological and neurochemical effects in addition to inhibition of MAO, and findings on these effects have ...
D. Matveychuk   +8 more
semanticscholar   +1 more source

Evolution of ideas about the risk of tyramine syndrome developing during therapy with irreversible non-selective monoamine oxidase inhibitors (to the 70th anniversary of the first use of this group of antidepressants)

open access: yesНеврология, нейропсихиатрия, психосоматика, 2022
We describe the history of studying of the problem of tyramine syndrome during the treatment with antidepressants, irreversible non-selective monoamine oxidase inhibitors. Data on clinical observations are presented.
D. S. Danilov, M. Yu. Brovko
doaj   +1 more source

The History of Irreversible Non-Selective MAOI Antidepressants in Russia (for their 70th Anniversary)

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2023
The history of irreversible non-selective MAOI antidepressants in the USSR and Russia is systemized. The history of representatives’ appearance is described. The history of the study of pharmacological effects is highlighted.
D. S. Danilov
doaj   +1 more source

Monoamine oxidase inhibitors and neuroprotective mechanisms

open access: yesPsychiatry and Clinical Psychopharmacology, 2021
There has been a resurgence of interest in recent years in monoamine oxidase inhibitors, primarily because of the demonstrated neuroprotective and/ or neurorescue properties of several of these drugs in a variety of toxic situations in vivo and in vitro.
Glen Baker   +4 more
doaj   +1 more source

Drug-Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System. [PDF]

open access: yesJ Clin Hypertens (Greenwich)
ABSTRACT Hypertension exerts a significant global disease burden, adversely affecting the well‐being of billions. Alarmingly, drug‐related hypertension remains an area that has not been comprehensively investigated. Therefore, this study is designed to utilize the adverse event reports (AERs) from the US Food and Drug Administration's Adverse Event ...
Zhu H, Pan L, Lui H, Zhang J.
europepmc   +2 more sources

Role of MAOI drugs as triggers of manic episodes in bipolar disorders: A case report and a narrative review

open access: yesEuropean Psychiatry, 2022
Introduction Use of Monoamine Oxidase Inhibitors (MAOIs) has experimented an important reduction in recent years, being replaced by other antidepressant drugs (ADs) associated with a better safety profile.
L. Olivier Mayorga   +5 more
doaj   +1 more source

Clomipramine Induced Extrapyramidal Symptoms: A Case Series [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2023
Extra Pyramidal Symptoms (EPS) are a group of symptoms that include dystonia, bradykinesia, tremor, akathisia, and tardive dyskinesia. They are caused by the blockage of D2 receptors in the nigro-striatal pathway and the imbalanced acetyl choline ...
Disha Mukherjee   +2 more
doaj   +1 more source

A meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators [PDF]

open access: yes, 2017
INTRODUCTION: Social anxiety disorder (SAD) is among the most prevalent mental disorders, associated with impaired functioning and poor quality of life. Pharmacotherapy is the most widely utilized treatment option.
Borenstein M   +8 more
core   +2 more sources

HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. [PDF]

open access: yes, 2017
Most studies of HIV latency focus on the peripheral population of resting memory T cells, but the brain also contains a distinct reservoir of HIV-infected cells in microglia, perivascular macrophages, and astrocytes.
Alvarez-Carbonell, David   +4 more
core   +1 more source

HR-MS Analysis of the Covalent Binding of Edaravone to 5-Formylpyrimidine Bases and a DNA Oligonucleotide Containing a 5-Formylcytidine Residue. [PDF]

open access: yesRapid Commun Mass Spectrom
ABSTRACT Rationale Edaravone (EDA) is a radical scavenger and an antioxidant drug approved to treat amyotrophic lateral sclerosis and used as a research tool to explore treatment of neurodegenerative diseases and cancers. It is also a reactive agent, known as PMP (1‐phenyl‐3‐methyl‐5‐pyrazolone), used for the analysis of polysaccharides composition ...
Regnault R   +5 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy